Compare PCYO & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCYO | NKTR |
|---|---|---|
| Founded | 1976 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.5M | 2.2B |
| IPO Year | 1995 | 1996 |
| Metric | PCYO | NKTR |
|---|---|---|
| Price | $11.06 | $64.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $146.67 |
| AVG Volume (30 Days) | 56.0K | ★ 1.2M |
| Earning Date | 04-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.50 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | $1,227,787.00 | ★ $307,711,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.57 | ★ N/A |
| Revenue Growth | ★ 171.54 | 86.00 |
| 52 Week Low | $9.65 | $21.02 |
| 52 Week High | $12.44 | $109.00 |
| Indicator | PCYO | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 49.36 |
| Support Level | $10.71 | $64.30 |
| Resistance Level | $10.96 | $66.52 |
| Average True Range (ATR) | 0.36 | 3.38 |
| MACD | 0.01 | 1.26 |
| Stochastic Oscillator | 48.15 | 53.70 |
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.